Using Existing Drugs as Leads for Broad Spectrum Anthelmintics Targeting Protein Kinases
暂无分享,去创建一个
[1] W. Evans,et al. Etoposide pharmacokinetics in patients with normal and abnormal organ function. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] F. Milord,et al. DIFLUOROMETHYLORNITHINE FOR ARSENO-RESISTANT TRYPANOSOMA BRUCEI GAMBIENSE SLEEPING SICKNESS , 1987, The Lancet.
[3] J. Jackson,et al. Determination of neomycin in plasma and urine by high-performance liquid chromatography. Application to a preliminary pharmacokinetic study. , 1991, Journal of chromatography.
[4] D. Alberts,et al. Phase I and pharmacokinetic study of etoposide phosphate , 1995, Anti-cancer drugs.
[5] D. Brownlee,et al. Actions of the anthelmintic ivermectin on the pharyngeal muscle of the parasitic nematode, Ascaris suum , 1997, Parasitology.
[6] S. Steinberg,et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Sean R. Eddy,et al. Profile hidden Markov models , 1998, Bioinform..
[8] P. Cohen,et al. The regulation of protein function by multisite phosphorylation--a 25 year update. , 2000, Trends in biochemical sciences.
[9] J Mottram,et al. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. , 2000, Chemistry & biology.
[10] D. Jasmer,et al. Multiple lethal effects induced by a benzimidazole anthelmintic in the anterior intestine of the nematode Haemonchus contortus. , 2000, Molecular and biochemical parasitology.
[11] P. Cohen. The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture. , 2001, European journal of biochemistry.
[12] B. Rollins,et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] E. Sausville,et al. Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development , 2002, The Annals of pharmacotherapy.
[14] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[15] R. Rao,et al. IN VITRO EFFECTS OF ANTIBIOTICS ON BRUGIA MALAYI WORM SURVIVAL AND REPRODUCTION , 2002, The Journal of parasitology.
[16] Shyam Sundar,et al. Oral miltefosine for Indian visceral leishmaniasis. , 2002, The New England journal of medicine.
[17] K. Heidenreich,et al. Pyridinylimidazole p38 mitogen-activated protein kinase inhibitors block intracellular Toxoplasma gondii replication. , 2002, International Journal of Parasitology.
[18] J. Bubis,et al. Protein Kinase CK1 from Trypanosoma cruzi , 2003, Journal of protein chemistry.
[19] P. Zipfel,et al. Isolation and characterization of the regulatory subunit of cAMP-dependent protein kinase from the filarial parasite Onchocerca volvulus. , 2003, Molecular and biochemical parasitology.
[20] C. Stoeckert,et al. OrthoMCL: identification of ortholog groups for eukaryotic genomes. , 2003, Genome research.
[21] P. Cohen,et al. Signalling pathways involved in multisite phosphorylation of the transcription factor ATF‐2 , 2004, FEBS letters.
[22] Ian A Blair,et al. Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[23] E. Cook,et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. , 2004, Blood.
[24] C. Doerig. Protein kinases as targets for anti-parasitic chemotherapy. , 2004, Biochimica et biophysica acta.
[25] G. Manning. Genomic overview of protein kinases. , 2005, WormBook : the online review of C. elegans biology.
[26] Trevor C. Y. Kwok,et al. A small-molecule screen in C. elegans yields a new calcium channel antagonist , 2006, Nature.
[27] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[28] Scott N. Boyle,et al. Dissecting kinase signaling pathways. , 2007, Drug discovery today.
[29] Gabriele Ausiello,et al. MINT: the Molecular INTeraction database , 2006, Nucleic Acids Res..
[30] Lindy Holden-Dye,et al. Anthelmintic drugs. , 2007, WormBook : the online review of C. elegans biology.
[31] T. Curiel,et al. Drugs Designed To Inhibit Human p38 Mitogen-Activated Protein Kinase Activation Treat Toxoplasma gondii and Encephalitozoon cuniculi Infection , 2007, Antimicrobial Agents and Chemotherapy.
[32] Jonathan E. Allen,et al. Draft Genome of the Filarial Nematode Parasite Brugia malayi , 2007, Science.
[33] J. Foster,et al. Mining Predicted Essential Genes of Brugia malayi for Nematode Drug Targets , 2007, PloS one.
[34] G. Barton,et al. Classification and functional annotation of eukaryotic protein kinases , 2007, Proteins.
[35] F. Lee,et al. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL , 2008, Cancer Chemotherapy and Pharmacology.
[36] Drug discovery: Fresh hope to can the worms , 2008, Nature.
[37] H. Rees,et al. siRNA-mediated knockdown of a splice variant of the PK-A catalytic subunit gene causes adult-onset paralysis in C. elegans. , 2008, Gene.
[38] Graziano Pesole,et al. Genome sequence of the metazoan plant-parasitic nematode Meloidogyne incognita , 2008, Nature Biotechnology.
[39] K. Brehm,et al. Characterization and inhibition of a p38-like mitogen-activated protein kinase (MAPK) from Echinococcus multilocularis: antiparasitic activities of p38 MAPK inhibitors. , 2008, Biochemical pharmacology.
[40] W. Humphreys,et al. Biotransformation of [14C]Dasatinib: In Vitro Studies in Rat, Monkey, and Human and Disposition after Administration to Rats and Monkeys , 2008, Drug Metabolism and Disposition.
[41] P. Lechat,et al. Rho kinase inhibition in severe malaria: thwarting parasite-induced collateral damage to endothelia. , 2008, The Journal of infectious diseases.
[42] P. Green,et al. Massively parallel sequencing of the polyadenylated transcriptome of C. elegans. , 2009, Genome research.
[43] Robert D. Finn,et al. InterPro: the integrative protein signature database , 2008, Nucleic Acids Res..
[44] Michael D. Urbaniak. Casein kinase 1 isoform 2 is essential for bloodstream form Trypanosoma brucei , 2009, Molecular and biochemical parasitology.
[45] Makedonka Mitreva,et al. Helminth Genomics: The Implications for Human Health , 2009, PLoS neglected tropical diseases.
[46] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[47] E. van den Enden. Pharmacotherapy of helminth infection. , 2009, Expert opinion on pharmacotherapy.
[48] R. Eglen,et al. The current status of drug discovery against the human kinome. , 2009, Assay and drug development technologies.
[49] Cheuk-Man Yu,et al. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. , 2010, Drug discovery today.
[50] Dirk Repsilber,et al. ExprEssence - Revealing the essence of differential experimental data in the context of an interaction/regulation net-work , 2010, BMC Systems Biology.
[51] C. Chapus,et al. cAMP-dependent protein kinase from Plasmodium falciparum: an update , 2010, Parasitology.
[52] Trey Ideker,et al. Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..
[53] M. Mitreva,et al. Gender-Associated Genes in Filarial Nematodes Are Important for Reproduction and Potential Intervention Targets , 2011, PLoS neglected tropical diseases.
[54] D. Fong,et al. Crystal Structures of Two Aminoglycoside Kinases Bound with a Eukaryotic Protein Kinase Inhibitor , 2011, PloS one.
[55] T. Curiel,et al. Human p38 mitogen-activated protein kinase inhibitor drugs inhibit Plasmodium falciparum replication. , 2011, Experimental parasitology.
[56] Chris Morley,et al. Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.
[57] Elaine R. Mardis,et al. The draft genome of the parasitic nematode Trichinella spiralis , 2011, Nature Genetics.
[58] R. Campbell,et al. Target repurposing for neglected diseases. , 2011, Future medicinal chemistry.
[59] Mindy I. Davis,et al. Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.
[60] Makedonka Mitreva,et al. Targeting Protein-Protein Interactions for Parasite Control , 2011, PloS one.
[61] Makedonka Mitreva,et al. HelmCoP: An Online Resource for Helminth Functional Genomics and Drug and Vaccine Targets Prioritization , 2011, PloS one.
[62] Zhengyuan O. Wang,et al. Transcription profiling reveals stage- and function-dependent expression patterns in the filarial nematode Brugia malayi , 2012, BMC Genomics.
[63] D. Virshup,et al. Casein kinase 1: Complexity in the family. , 2011, The international journal of biochemistry & cell biology.
[64] John C. Martin,et al. Nematode.net update 2011: addition of data sets and tools featuring next-generation sequencing data , 2011, Nucleic Acids Res..
[65] R. Martin,et al. Selective effect of the anthelmintic bephenium on Haemonchus contortus levamisole-sensitive acetylcholine receptors , 2012, Invertebrate Neuroscience.
[66] Kimberly Van Auken,et al. WormBase 2012: more genomes, more data, new website , 2011, Nucleic Acids Res..